clinical trial · NCT07465029
A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain
Bristol-Myers Squibb·—·active not recruiting·n = 1,300
Lower-risk Myelodysplastic Syndromes (TD LR-MDS)Erythropoiesis-stimulating agents (ESAs)LuspaterceptLenalidomideHypomethylating agents (HMAs)Reb blood cell transfusion
brief summary
The purpose of this study is to understand the incidence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS) and describing real-world first-line treatment patterns, healthcare resource utilization, and associated clinical outcomes in adult patients with TD LR-MDS in Spain
started
Feb 2, 2026
primary completion
Mar 31, 2026
completion
May 31, 2026
last updated
Mar 11, 2026
official title
Observational Retrospective Study on Incidence, First-line Treatment Patterns, and Clinical Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain Using the BIG-PAC® Database
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol